Skip to main content
Figure 1 | Journal of Hematology & Oncology

Figure 1

From: Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

Figure 1

Schematic representation of the MDM2 and p53 proteins, and the binding areas for small-molecule inhibitors. Nutlin, cis-imidazoline; TDP, benzodiazepinedione; MI, spiro-oxindoles; PXN, isoquinolinone; HLI98, 5-deazaflavin; JNJ-26854165, tryptamine; RITA, thiophene; RING, really interesting new gene (signature domain of E3 ligase). Binding of either HLI98 or JNJ-26854165 to RING domain of MDM2 can block the interaction of ubiquitinated MDM2-p53 protein complex to the proteasome.

Back to article page